Primary glaucoma
Conditions
Interventions
A:Phaco+IOL+AGV
B:Phaco+IOL+GSL
Sponsors
Beijing Tongren Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Voluntarily signed informed consent form for this study; 2. Chinese male or female patients aged 50-80 years old (including 50 and 80 years old); 3. Patients who met the diagnosis of primary angle closure glaucoma (PACG) with moderate visual field defect and received Phaco+IOL implantation combined with AGV implantation were included in this study. Patient who met the clinical diagnosis of primary angle closure glaucoma (PACG) with intermediate visual field defect and received Phaco+IOL implantation combined with GSL; 4. Combined cataract.
Exclusion criteria
Exclusion criteria: 1. Acute primary angle-closure (APAC) or PACG acute onset eye; 2. Unable or unwilling to sign consent forms, follow study procedures, or cooperate with eye examinations; 3. Secondary angle-closure glaucoma: Lens dislocation, uveitis, trauma, and neovascular glaucoma; 4. Previous surgery or anticipated need for additional surgery (except laser iridotomy) : previous cyclodestructive surgery, cataract surgery with or without intraocular lens implantation; Aphasic eyes; Expected need for other eye surgery or other eye operations, etc.; 5. Complicated with other eye diseases or abnormalities: including corneal abnormalities or corneal infection; Iridocorneal endothelial syndrome, anterior segment hypoplasia, nanophthalmos, high myopia (> 6.0D), uveitis, ocular tumors, ocular trauma, fundus lesions such as central retinal vein occlusion, central retinal artery occlusion, retinal detachment, etc.; 6. Pregnant or lactating women or with a history of serious systemic diseases: Patients with diabetes mellitus, hypertension (systolic blood pressure, >= 180mmHg or diastolic blood pressure, >= 100mmHg), advanced cardiac, renal, respiratory, or cancer; 7. For whom autoimmune conditions require long-term use of topical or systemic hormones or for whom hormone therapy is indicated.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraocular pressure, IOP; | — |
Secondary
| Measure | Time frame |
|---|---|
| complication;Best corrected visual acuity, BCVA;Visual sight;Cup to plate ratio, C/D; | — |
Countries
China
Contacts
Public ContactZhigang Fan
Beijing Tongren Hospital, Capital Medical University
Outcome results
None listed